BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv6.6.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.biomed.cas.cz
X-WR-CALDESC:Akce na 
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Prague
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Prague:20240515T150000
DTEND;TZID=Europe/Prague:20240515T160000
DTSTAMP:20260525T213600
CREATED:20240506T070531Z
LAST-MODIFIED:20240506T070531Z
UID:888-1715785200-1715788800@www.biomed.cas.cz
SUMMARY:Seminář Milan Reiniš\, Ph.D.
DESCRIPTION:“Targeting the STAT3 signaling pathway in cancer and senescence” \nSTAT3 signaling pathway plays important roles in many cellular processes\, such as cell differentiation\, carcinogenesis\, cellular senescence or regulation of the immune responses. The STAT3 molecule thus represents an attractive therapeutic target. However\, its druggability is still questionable. We have tested a number of small molecules designed to inhibit STAT3 phosphorylation for their inhibitory capabilities and impacts on the tumor cell growth. Importantly\, we have documented that selected compounds with limited cytotoxicity were able to inhibit secretion of immunosuppressive cytokines by senescent cells. These results suggest that the STAT3 inhibitors could serve as senomodulatory agents.
URL:https://www.biomed.cas.cz/event/seminar-milan-reinis-ph-d/
LOCATION:Posluchárna Milana Haška / Milan Hašek Auditorium
ORGANIZER;CN="%C3%9AMG":MAILTO:leona.krausova@img.cas.cz
END:VEVENT
END:VCALENDAR